AU Patent

AU2016219231B2 — Benzenesulfonamide upregulators of NPC1 for neimann-pick disease and other lysosomal storage disorders

Assigned to Icahn School of Medicine at Mount Sinai · Expires 2020-08-20 · 6y expired

What this patent protects

Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds is shown in formula I:

USPTO Abstract

Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds is shown in formula I:

Drugs covered by this patent

Patent Metadata

Patent number
AU2016219231B2
Jurisdiction
AU
Classification
—
Expires
2020-08-20
Drug substance claim
No
Drug product claim
No
Assignee
Icahn School of Medicine at Mount Sinai
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.